Xeljanz is a Janus kinase (JAK) inhibitor. It helps treat active psoriatic arthritis, moderate to severe ulcerative colitis, and moderate to severe rheumatoid arthritis. The manufacturer of this product is Pfizer, a pharmaceutical company.
What is it made of?
Xeljanz is made of tofacitinib, an ingredient with JAK inhibiting properties. It interrupts the JAK pathway to prevent Signal Transducers and Activators of Transcription (STATs) from being phosphorylated and activated. The formula also contains excipients such as croscarmellose sodium, titanium dioxide, triacetin, and lactose monohydrate. The package insert can be referred to for further details.
What are its uses?
Xeljanz is used to treat patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. This product can be used in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs. As well, this product can be used as a monotherapy. Xeljanz is also used to treat moderately to severely active ulcerative colitis patients. Patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) can use this product.
How long do its effects last?
The elimination half-life of Xeljanz is about three hours. Peak plasma concentrations are reached in approximately a half hour to an hour.